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Abstract

Author Manuscript

Inflammation promotes healing in myocardial infarction but if unresolved, it leads to heart failure.
To define the inflammatory and resolving responses, we quantified leukocyte trafficking and
specialized proresolving mediators (SPMs) in the infarcted left ventricle and spleen after
myocardial infarction, with the goal of distinguishing inflammation from its resolution. Our data
suggest that the spleen not only served as a leukocyte reservoir but also was the site where SPMs
were actively generated after coronary ligation in mice. Before myocardial infarction, SPMs were
more abundant in the spleen than in the left ventricle. At day 1 after coronary ligation, the spleen
was depleted of leukocytes, a phenomenon that was associated with greater numbers of leukocytes
in the infarcted left ventricle and increased generation of SPMs at the same site, particularly
resolvins, maresin, lipoxins, and protectin. In addition, the infarcted left ventricle showed
increased expression of genes encoding lipoxygenases and enhanced production of SPMs
generated by these enzymes. We found that macrophages were necessary for SPM generation. The
abundance of SPMs in the spleen before myocardial infarction and increased SPM concentrations
in the infarcted left ventricle within 24 hours after myocardial infarction were temporally
correlated with the resolution of inflammation. Thus, the acute inflammatory response coincided
with the active resolving phase in post-myocardial infarction and suggests that further
investigation into macrophage-derived SPMs in heart failure is warranted.
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Leukocytes mobilize to the heart and may be the source of inflammation-resolving lipids after
myocardial infarction.
Leukocytes mobilize from the spleen to the ischemic heart and generate inflammation-resolving
lipids after myocardial infarction.

Editor’s summary: Calming the heart after a heart attack

Author Manuscript

Although leukocytes can trigger inflammation that aggravates a heart attack, they can also produce
bioactive resolving mediators that suppress inflammation. Halade et al. tracked leukocyte
populations and measured the concentrations of pro-resolving bioactive mediators that attenuate
inflammation in mice subjected to coronary ligation, an experimental method of inducing
myocardial infarction that progresses to irreversible heart failure. Their analysis suggests that
leukocytes were mobilized from the spleen to the infarcted heart to produce pro-resolving
mediators and specific depletion of macrophages was associated with the lack of pro-resolving
mediators biosynthesis. Thus, generally preventing immune cell infiltration after a heart attack
may also delay healing and recovery by allowing inflammation to continue abated.

Introduction

Author Manuscript

Chronic and non-resolving inflammation is a prominent factor in cardiovascular diseases,
particularly in heart failure (HF) pathology following myocardial infarction (MI) (1–3).
After MI, self-healing occurs in mice but not in humans. Mammals respond to an acute
injury by trafficking leukocytes to the injury site, which generate eicosanoids such as
prostaglandins (PGs) and leukotrienes (LTs) from essential and conditional fatty acids and
many cytokines and chemokines (4, 5). To control MI-mediated inflammation or infectioninduced myocarditis, diverse leukocytes (neutrophils, monocytes/macrophages) have a major
role in resolving inflammation; however, the role of leukocytes in resolving phase still
remains unclear in myocardial healing. Given the excessive inflammation in chronic HF
patients, it is critical to understand the sequential healing mechanism(s) in mice to identify
new targets to delay pathological left ventricle (LV) remodeling in HF.

Author Manuscript

Traditionally, post-MI healing and outcome is divided into three phases. The initiation phase
encompasses the initial minutes to hours or few days of the acute inflammatory phase. The
resolution phase lasts a few days to weeks and encompasses the reparative or resolving
phase. Finally, the progression phases lasts weeks to months or years depending on the
resolution phase, which if defective, leads to LV dysfunction, chronic HF, morbidity and
mortality (6). Current research focuses on the acute inflammatory response, with the notion
that the presence of neutrophils or a differential subset of monocyte/macrophages are the
hallmark of inflammation and that therefore controlling inflamed leukocytes will offer
cardioprotection (7). However, multiple approaches in >20,000 papers have shown ways to
reduce infarct size but these results have rarely been translated to therapeutic products (8).
Therefore, we sought to quantify the acute and resolving response in a temporal-spatial
manner post-MI.
In the post-MI initiation phase, ~50% of leukocytes travel from the splenic reservoir through
the circulation to the site of LV injury that generates edematous inflammatory milieu but
Sci Signal. Author manuscript; available in PMC 2018 September 19.
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these leukocytes have not been chemically quantitated to decode their phenotype (9). We
hypothesized that splenic leukocytes actively participated in LV healing and govern the
resolution of inflammation through generating specialized proresolving mediators (SPMs)
(Figure 1A). SPMs are bioactive lipid mediators that include lipoxins, resolvins, protectins
and maresins and are enzymatically produced during the resolution of inflammation (10).
Neutrophils and monocyte/macrophages populate the infarcted area that shows LV
dysfunction (fractional shortening <15%) post-MI. Here, we determined the temporal
dynamics of inflammation and resolution in the acute and resolving phases in the LV and
spleen post-MI. Thus, the present report suggests that splenic leukocytes, particularly
macrophages, promote LV healing by generating SPMs and mobilizing precursor fatty acid
substrates. These results show that leukocyte turnover is essential for acute LV healing by
amplifying the generation of SPMs at the site of injury that help to resolve inflammation.

Author Manuscript

Although lipid metabolizing enzymes such as lipoxygenase (LOX) and cyclooxygenase
(COX) have been investigated for the their ability to resolve inflammation post-MI (11),
COX-2 inhibition results in more MI events for patients (12). Therefore, we attempted to
determine the temporal role(s) of LOXs and COXs in SPM appearance for LV healing postMI. LOXs generated bioactive(s) in the LV, while COXs generated prostanoids in the spleen
to promote successful resolution of inflammation. Thus, these results demonstrate that
during post-MI healing, the essential innate acute response coincides with the resolving
phase during which LOX-mediated SPMs are generated in the infarcted LV in HF pathology.

Results
LOX expression increases in the infarcted LV to generate SPMs post-MI.

Author Manuscript
Author Manuscript

In mice subjected to permanent coronary ligation (Fig. 1A), the spleen displayed decreased
weight (Table 1), potentially because of splenic leukocyte mobilization to the infarcted area.
Further, the LV displayed a significant weight increase due to the edema that is characteristic
of MI, stroke and other ischemic injury (Table 1). We evaluated naïve control mice and postMI at day 1 (d1) and day 5 (d5) for LV geometry, fractional shortening and infarct area.
Long axis B-mode with speckle tracking analyses showed reduced fractional shortening,
strain and strain rate recapitulates post-MI structural HF pathology (Fig. 1B–D). The
histology of LV mid-cavity sections indicated progressive dilation, wall thinning and signs
of acute HF pathology in post-MI mice at d1 and d5 (Fig. 1E–F). Thus, MI-induced LV
remodeling was marked with dilation-induced changes in LV size, function and geometry
with splenic leukocyte depletion and marked edematous milieu in the LV and lung post-MI
(Table 1 and Fig. S1, A to D). Gene expression analysis showed that genes encoding LOXs
involved in initiating SPM production showed higher levels in the infarcted LV compared to
those in the spleen (Fig. 1G–I). ALOX15 peaked in the LV infarcted area within 24 hours
post-MI and returned to naïve control levels by d5 post-MI (Fig. 1G), while ALOX5 and
ALOX12 showed sustained increases in expression in the infarcted LV and spleen at d1 to
d5 post-MI compared to d0 naïve controls (Fig. 1H–I). COX-1 (which is constitutively
expressed) and COX-2 (which is inducibly expressed) were significantly higher in the spleen
than the LV both pre- and post-MI. COX-1 showed increased expression in spleen post-MI
but decreased expression in infarcted LV at d1 post-MI. Post-MI COX-2 expression was

Sci Signal. Author manuscript; available in PMC 2018 September 19.

Halade et al.

Page 4

Author Manuscript

increased in spleen and LV within 24 hours which was sustained until d5 (Fig. 1J–K). Thus,
MI-induced, organ-specific differential expression of genes encoding LOXs and COXs in the
acute response may lead to diversified docosanoid and prostanoid production in the LV postMI.
Increased LOX expression is associated with D-series SPM production in the infarcted LV
post-MI

Author Manuscript
Author Manuscript

Because the expression of LOX- and COX-encoding genes were differentially increased in
the infarcted LV and post-MI spleens, we measured the LOX and COX-derived SPM
resolution metabolome in the LV to confirm increased activity. In response to MI at d1,
SPMs in the infarcted LV were increased ~4.5 fold compared to no-MI naïve controls (Fig.
2A) while the spleen SPMs were decreased ~1.4 fold compared to naïve control at d1 postMI. By day 5 post-MI, SPMs in the infarcted LV were further increased, suggesting
continuous resolution, and the spleen returned to baseline SPM levels comparable to those in
naïve controls (Fig. 2B). In the initiation phase of MI, with acute leukocyte infiltration in the
infarcted LV, the DHA metabolome amplified and peaked with significant increases in
resolvins, protectin and mareisn (RvD1, RvD3, RvD4, RvD5, RvD6, AT-RvD1, PD1, MaR1,
7S,14S-diHDHA and 4S,14S-diHDHA) compared to naïve controls and d5 post-MI that
were each identified using LC-MS-MS (Table S1, Fig. S2 A–B and Fig. S3 A–B). Likewise,
single E-series resolvin (RvE2) was increased from eicosapentaenoic acid (EPA)
metabolome at d1 post-MI compared to no-MI (Table S1, Fig. S2 A–B and Fig. S3 A–B). In
the arachidonic acid (AA) metabolome, the infarcted LV showed significant increases in the
lipoxins and prostaglandins (LXB4, AT-LXA4, 5S,15S-diHETE, 5S,12S-diHETE and
PGF2α) compared to no-MI and d5 post-MI (Table S1, Fig. S2 A–B and Fig. S3 A–B). From
initiation to termination of the acute phase, LXA4, PGD2, TXB2 and AT-PD1 were showed
sustained increase in response to MI compared to no-MI naïve controls. Thus, splenic
leukocyte trafficking to the infarcted LV coincides with the peak of temporal D-series
resolution metabolome post-MI.
Splenic leukocytes activated Class Switching SPM generation in spleen and infarcted LV
post-MI

Author Manuscript

The spleen serves as an active site for extramedullary monocytopoiesis post-MI in mice (13).
In the clinical setting, spleen metabolic activity defines the future HF risk (14); therefore, we
determined the splenic SPM resolution metabolome (D- and E-series resolvins, maresin,
protectin and lipoxins) pre and post-MI. (Fig. 2A–B). We found that the spleen not only
supplied leukocytes post-MI but was also the site of SPM biosynthesis. These SPMs
included RvD1, RvD4, LXB4, and the prostaglandins PGD2, PGE2 and PGF2α (Table S2).
Of note, naïve spleen contained higher levels of leukocyte class-switching SPMs such as
RvD5, RvD6, PD1, AT-PD1, MaR1, LXA4, AT-LXA4, AT-LXB4 compared to naïve LV (~
<10 pg/50 mg LV tissue) (Fig. 2A). We also measured the fatty acids from which SPMs are
generated. Post-MI extramedullary monocytopoiesis in spleen was accompanied by
mobilization and increased amounts of the fatty acids (AA; arachidonic acid, DHA;
docosahexaenoic acid and EPA; eicosapentaenoic acid) at d1 post-MI (Tables S1 and S2;
Fig. 2A and 2B). To understand whether resolution metabolome kinetics ran parallel with
leukocyte kinetics, we next performed detailed temporal analysis of cellular infiltration in
Sci Signal. Author manuscript; available in PMC 2018 September 19.
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the post-MI LV and spleen at d1 and d5 post-MI. The total number of infiltrating CD45+/
CD11b+ leukocytes gradually increased after MI from d1 to d5. Infarcted LV had more
CD45+/CD11b+ leukocytes at d1 (4 fold) and at d5 (9 fold) compared to spleen post-MI
(Fig. S4 A–B). Furthermore, the F4/80+ population was increased in both LV and spleen,
with a greater accumulation of F4/80+ cells at d5 post-MI in infarcted LV compared to
spleen (Fig. 3A and 3B). The MI-induced leukocyte-derived chemoattractant LTB4 promotes
adhesion and infiltration of neutrophils but lipoxins (LXA4 and LXB4) also regulate
leukocyte infiltration and clearance to turn on resolving responses. Naïve spleen showed
higher levels of LTB4 which decreased with time by d5 post-MI. Leukocytes were mobilized
from spleen to infarcted LV, as suggested by the presence of higher levels of LTB4-induced
inflammation and lower levels of LTB4 in spleen from d1-d5 post-MI (Fig. 3C). In contrast,
LXB4 and AT-LXA4 spiked at d1 post-MI, particularly in the spleen (Fig. 3D–E). Consistent
with neutrophils (Ly6G+) being the first responders, they were activated and infiltrated the
infarcted LV, peaking at d1 post-MI both in LV and spleen; notably, the percentage of Ly6G+
cells significantly dropped from d1 to d5 post-MI in LV and spleen (Fig. 4A–B). Neutrophil
recruitment peaked within 24 h, which coincided with the increase in RvD1 in spleen and
RvD1 and RvD5 in infarcted LV. These results suggested that D-series Rvs are produced in a
site specific manner (Fig. 4C–D). Numerically, macrophages were the predominant cells in
the infarcted LV and peaked at d5 post-MI. The macrophages showed a biphasic pattern of
activation on the basis of Ly6C expression (Fig. 5A). M1 (Ly6Chigh; Fig. 5B) macrophages
dominated d1 post-MI, whereas M2 (Ly6Clow; Fig. 5C) macrophages increased more
gradually and peaked at d5 post-MI in LV. Maresin 1 (MaR1; macrophage mediators in
resolving inflammation) levels were relatively higher in spleen before MI; after leukocyte
mobilization, MaR1 was lowered in spleen but spiked in the infarcted LV post-MI,
suggesting that the spleen not only acts as a source of SPMs but may supplied the cells that
produce SPMs at the site of injury (Fig. 5D). Thus, the leukocytes are activated
simultaneously in the spleen and infarcted LV post-MI; however, SPM biosynthesis is higher
in the infarcted LV compared to spleen post-MI.
Splenic leukocytes expand in the infarcted LV and acquire resolving phenotypes post-MI

Author Manuscript

Next, we assessed the pro-inflammatory and alternatively activated subset of neutrophils and
macrophages in the infarcted LV and post-MI spleen. At d5 post-MI, the LV had more Ly6G
+/CD206+ (N2) neutrophils compared with spleen (Fig. 6A–B). CD206 expression indicates
resolving phenotypic variability of neutrophils and macrophages. We observed higher
number of CD206+ neutrophils at d1 and d5 post-MI in infarcted LV compared with spleen
(Fig. 6A and B). Splenic leukocyte recruitment and regulation of innate inflammatory cells
is necessary to prevent non-resolving inflammation and to achieve controlled repair (3, 9).
We validated that infarcted LV and post-MI spleens contained a higher percentage of CD11b
+F4/80+ macrophages compared to the naive control which displayed a biphasic pattern on
the basis of CD206 expression. At d1 post-MI d1, Ly6G−/CD206+ (Fig. 6C), Ly6G+/
CD206+ (Fig. 6D), Ly6ChighCD206+ (Fig. 6E) macrophages were significantly increased in
the infarcted LV, suggesting that alternatively activated macrophages and neutrophils were
increased within 24 h. Resolving macrophages (Ly6ClowCD206+) began to increase at d1
and peaked at d5 post-MI in the LV compared to spleen and no-MI control (Fig. 6F). Thus,
splenic leukocytes were primarily expanded to resolving phenotypes in the infarcted LV,
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suggesting progression towards resolution of inflammation post-MI. However, neutrophil
and macrophage variability extends beyond classifications of pro-inflammatory M1 or N1
and resolving M2 or N2 phenotypes which depend on the generation of class switching
SPMs in the infarcted LV and spleen post-MI (15).
Depletion of macrophages reduces LOX expression and SPM generation post-MI

Author Manuscript

Since macrophages are centrally involved in myocardial healing in mice and depletion of
macrophages magnifies post-MI mortality, we assessed the macrophage-derived lipid
mediator secretome after injecting mice with clodronate (CLD) liposomes to deplete
macrophages (Fig. 7A). Flow cytometry data indicated that CLD-injected mice had a ~2.5
fold decrease in monocytes (CD11b+/CD45+) and macrophages (CD11b+/F4/80+) in spleen
and a ~1.4 fold decrease in the infarcted LV within 24 h compared to MI-control, confirming
post-MI leukocyte depletion (Fig. 7B–E). In response to CLD-mediated depletion, ALOX15
(Fig. 7F), ALOX12 (Fig. 7G), and ALOX5 (Fig. 7H) mRNA expression were decreased
while COX-2 (Fig. 7I) and COX-1 (Fig. 7J) mRNA expression were increased in the
infarcted LV compared to MI-control. To validate the post-MI activity of LOXs and COXs in
spleen and infarcted LV, we used targeted metabolipidomics that emphasized SPMs. Only 3
SPMs (LXA4, AT-LXA4 and RvD4) were detected in the infarcted LV and spleen of CLDinjected mice (Fig. 7K, 7L, and 7M) compared to infarcted LV of MI control mice which
displayed high concentrations of SPMs (D- and E-series resolvins, protectins, maresin and
lipoxins) (Tables S1 and S2). Further, CLD-injected, post-MI infarcted LV and spleen
showed decreased levels of LTB4 (Fig. 7N), LXB4 (Fig. 7O), and PGE2 (Fig. 7P) compared
to MI-control (Tables S1 and S2, Fig. S5 A–B). These results showed that the macrophage
secretome contributed most of the SPMs during acute healing of the LV.

Author Manuscript

Resolving response proceeds to cytokine activation in the spleen and infarcted LV post-MI

Author Manuscript

Gene expression analysis for mRNAs encoding 84 inflammatory and adhesion molecules
suggested that the leukocyte population in the spleen may coordinate LV repair to resolve
post-MI inflammation (Fig. S6 and S7). The mRNAs encoding the pro-inflammatory
cytokine IL-1β and the monocyte trafficking marker Ccl2 were consistently higher in the
spleen than LV from d1 to d5 post-MI compared to naïve controls. Splenic mRNA levels of
Ccl2 and IL-1β were 12.5 and 1200 fold higher than infarcted LV respectively at d5 post-MI
(Fig. 8A and 8B). The levels of the mRNA encoding complement component C3 were
decreased within 24 h in both LV and spleen but increased 758 fold at d5 only in the
infarcted LV (Fig. 8C), suggestive of complement activation in later stage of post-MI in LV
healing. The expression of mRNAs encoding the resolving or reparative cytokines IL-10
(Fig. 8D), CXCL10 (Fig. 8E) and Ccr6 (Fig. 8F) peaked within 24h during the acute
inflammatory phase in spleen but took longer to increase in the infarcted LV about d5 postMI, suggesting that the cytokine response in the infarcted LV was increased during the
extended resolving phase at d5 post-MI. These results hint that the innate immune resolving
response could be simultaneously activated in the spleen and infarcted LV within 24 h of
post-MI. Thus, the resolving response coincides with the acute innate response characterized
by increased expression of mRNAs encoding reparative cytokines during LV healing postMI in mice.

Sci Signal. Author manuscript; available in PMC 2018 September 19.
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Discussion

Author Manuscript

Innate immune responsive neutrophils (CD11b+Ly6G+) and differential macrophages
(CD11b/Ly6Chigh and CD11b/Ly6Clow) are hallmarks of acute inflammation following
myocardial injury. HF individuals show elevated counts of leukocytes in the blood, inflamed
arterial wall, and infarcted myocardium post-MI. Post-MI, the spleen provides a steady flow
of leukocytes to the infarcted LV. The splenic myelopoiesis coordinates in a time-dependent
manner with infarcted LV to determine resolving and non-resolving inflammation in
myocardial remodeling (3, 16, 17). Using flow cytometry to identify immune cell
populations and LC-MS-MS based metabolomic profiling, we discovered that (i) the spleen
may store high levels of PGs (PGD2 and PGE2) and SPMs (RvD1, Maresin 1) and
macrophages may actively participate in SPM generation during infarcted LV repair (Fig.
8G); (ii) expression of specific LOX-encoding genes were higher in infarcted LV and
associated with SPM generation at this site (Fig. 8H); (iii) chemokine response is followed
by the cytokine response; and (iv) neutrophils and macrophages not only initiate the acute
inflammatory response but may also promote the resolving phase during LV healing.
Together, we provide critical knowledge of macrophage-derived SPMs and innate responsive
neutrophils and monocyte/macrophages phenotypes that may be therapeutically harnessed
without compromising self-defense mechanisms. Additionally, our results rationalize the
clinical speculation that splenic metabolic activity predicts the risk of future cardiovascular
events (14).

Author Manuscript

In contrast to the prevailing view that systemic leukocytes and macrophages are the part of
pathology leading to inflammatory milieu, we provide evidence that the macrophage
secretome of SPMs may be essential for resolving inflammation. Macrophages are present in
different organs and generate multiple autocrine and paracrine factors post-MI that are
involved in angiogenesis and myocardial healing (18, 19). Diversified subpopulations of
macrophages and neutrophils are essential for myocardial healing (15, 18). In addition, our
results suggest that macrophages actively produce SPMs in the infarcted LV and spleen to
promote resolution of inflammation. Leuschner et al. have shown that the post-MI spleen
generates monocytes that mobilize to the infarcted LV during acute inflammation. In this
process, the local death of neutrophils and monocytes/macrophages is major and the overall
cell clearance is minor (16).

Author Manuscript

Post-MI activated 5LOX not only synthesizes pro-inflammatory LTB4 to promote
recruitment of the leukocytes but also collectively biosynthesizes LXA4, LXB4, and ATLXA4, which is indicative of a resolution program at the site of myocardium injury. (3, 20).
Nuclear translocation of 5LOX is essential to generate pro-inflammatory LTB4, though
RvD1 prevents nuclear translocation of 5LOX, thereby suppressing LTB4 and enhancing
LXA4 production in macrophages (21). Thus, SPMs (such as RvD1, LXA4) can orchestrate
post-MI cardiac healing mechanisms involving the activation of lipoxin A4 receptor, thereby
reducing mobilization of cytosolic calcium and activation of the calcium-sensitive kinase
calcium-calmodulin-dependent protein kinase II (21, 22). Exogenous treatment of RvD1
also activates LXA4 and MaR1 in murine spleen, suggesting that SPMs act through
diversified feed-forward loops to promote resolution without altering acute response post-MI
(22). Binary categorization of macrophages and neutrophils into proinflammatory M1 and
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N1 and proresolving M2 and N2 subsets may be oversimplified but the heterogeneity of
M1/M2 or N1/N2 depends on the magnitude of LV injury and paracrine and autocrine role
of SPMs (15, 23). The particular leukocyte subset depends on activated COXs and LOXs,
availability of omega-3 and −6 fatty acids, and aging, which determine SPM levels in
resolving and pro-inflammatory milieu in post-MI healing (24) (Figure 8G–H). Whether the
SPMs expand residential macrophage population under the hemodynamic stress of
myocardial injury is an area of active research (1, 10, 25).

Author Manuscript

Comparison of metabololipidomics data from spleen and LV indicated that DHA was
enriched in spleen and that it was mobilized to the site of injury with leukocytes post-MI.
DHA can extend the life span of lupus prone mice (26). There is general consensus that
individuals should maintain balanced intake of n-3 and n-6 fatty acids for optimal health.
Dietary supplementation of n-3 fatty acids rich in DHA and EPA has emerged as a
preventive strategy to control inflammation in coronary heart disease (27). Imbalances in n-3
and n-6 fatty acids or excessive intake of n-6 fatty acids triggers non-resolving inflammation
in aged but not in young mice post-MI (24, 25). The nexus of essential fatty acids and the
biosynthesis of the resolution metabolome is an area of active research. Along these lines,
Endo et al. have created mice that overexpress the Caenorhabditis elegans fatty acid
desaturase (fat-1) to address discrepancies in dietary studies that can arise from individual
genetic and feeding variations. The fat-1 transgenic mice produce and store higher levels of
EPA and DHA in their organs and tissues thereby increasing levels of SPMs. After
transverse aortic constriction, fat-1 transgenic mice show reduced cardiac remodeling with
higher levels of EPA metabolites (28).

Author Manuscript

In summary, the present results provided evidence that post-MI splenic leukocyte infiltration
is not only the hallmark of acute inflammatory response but also primes the resolution phase
through the production of multiple families of SPMs to activate cardiac resolution program.
Future studies with pharmacological restoration of SPMs and on understanding the
proresolving role of SPMs are warranted in acute and chronic HF to advance resolution of
inflammation in LV tissue regeneration and homeostasis.

Materials and Methods
Animals

Author Manuscript

Male C57Bl/6J mice (stock number 000664) of 8 to 12 weeks were purchased from The
Jackson laboratory, USA. All animal experiments were conducted according to the “Guide
for the Care and Use of Laboratory Animals” (8th Edition. 2011), and AVMA Guidelines for
the Euthanasia of Animals: (2013 Edition) and were approved by the Institutional Animal
Care and Use Committee at the University of Alabama at Birmingham, USA.
Coronary artery ligation to induce myocardial infarction
Mice were anesthetized using continuous isoflurane (2 %) mixed in 100% oxygen through
inhalation and then intubated and ventilated with air using a small-animal respirator
(Harvard Apparatus, Holliston, MA, USA). The chest hairs were removed using depilatory
and a thoracotomy was performed in the fourth left intercostal space. The left atrium and
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ventricle were observed; the thin pericardium layer was then removed; and the left anterior
descending artery was permanently ligated with a 8–0 black polyamide monofilament suture
(ARO Surgical, T06A08N14–13) at the site of its emergence (23). Substantial blanching at
the LV ischemic area was considered indicative of successful coronary occlusion. The
thoracotomy was closed with four 6–0 blue monofilament sutures (Ethicon 6–0 Prolene
8697G). The endotracheal tube was detached once natural respiration resumed, and animals
were placed on a warm incubator maintained at 37°C until mice were completely awake (23,
29).
Transthoracic echocardiography

Author Manuscript

Heart function was measured by echocardiography with a 18–38 MHz transducer using
MX-400 Vevo 3100 (VisualSonics Inc., Toronto, Canada) at d0 as naïve control and d1 and
d5-post-MI. Mice were sedated with 1–2% isoflurane. Four-limb lead electrocardiograms
were simultaneously recorded along with echocardiography. LV fractional shortening (%)
was defined as [(EDD-ESD)/EDD] X 100, where EDD is LV end-diastolic dimension and
ESD is end-systolic dimension (23, 29).
LV strain and strain rate analysis

Author Manuscript

LV strain analysis is based on combined speckle tracking algorithms applied on highfrequency ultrasound images. Strain indicates how much the myocardial tissue has
deformed: Strain (S) = ΔL/L0 = (L1-L0)/L0. Strain rate reflects how fast the myocardial LV
tissue is deforming: Strain rate (SR) = S/Δt = ΔL/L0/Δt. Thus, strain and strain rate can
reflect the global systolic, diastolic and regional LV function. LV strain and strain rate were
quantified in the longitudinal, radial, and circumferential axes by speckle tracking of 2D
echocardiographic images acquired from the parasternal long- and short-axis views.
VevoStrain analyses were conducted by the trained investigator on all animals using
VisualSonics software. Short and long axis LV myocardium was automatically divided into
six parts for regional speckle tracking. The ultrasound operator was blinded to control and
post-MI day samples, which were decoded after strain analyses. (30).
Necropsy procedures for collecting infarcted LV and spleen and infarct area analysis

Author Manuscript

No-MI naïve controls, post-MI d1 and d5 mice were anesthetized under 2% isoflurane
anesthesia in 100% oxygen mix. To collect plasma, mice were injected with heparin (4
IU/g); blood was collected from the carotid artery under isoflurane anesthesia after 5
minutes; and the blood was centrifuged for 5 min to collect plasma. The chest cavity was
opened, and the left ventricle was perfused with 2–3 ml cardioplegic solution to remove
traces in LV, then the heart, lung and spleen were removed. The lungs and right and left
ventricles were collected, weighed and processed as previously described. From the first set
of mice, the infarcted LV was collected including the border zone from the apex towards the
base. The spleen was dissected by making incision in the left of peritoneal wall. Infarcted
LV and spleen (50 mg each) were snap-frozen for targeted metabololipidomic analyses.
From the second set of mice, the LV was divided into mid-cavity, apex and base to use the
LV mid-cavity for histological analysis and infarcted area for gene expression analyses. The
third set of infarcted LV and spleen was used for flow cytometry analyses. LV infarct was
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confirmed using 2,3,5-triphenyltetrazolium chloride staining at 37oC as described previously
(23, 31).
LV and spleen resolution metabololipidomics
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LV and spleen samples for LC-MS/MS analysis were extracted using solid phase extraction
(SPE) columns as described previously. Briefly, columns were equilibrated with 1 column
volume of methanol and 2 volumes ddH2O. Before extraction, 500 pg of deuterium-labeled
internal standards d8–5S-HETE, d4LTB4, d5LXA4, and d4PGE2 were added to facilitate
quantification of sample recovery. Sample supernatants were diluted with 10 volumes of
ddH2O, acidified (pH ~ 3.5) and immediately (< 20–30 seconds) loaded onto the SPE
column. After loading, columns were washed with 1 volume of neutral ddH2O followed by
hexane. Extracted samples were eluted with 6 ml methyl formate and taken to dryness using
Speedvac or nitrogen stream. Samples were suspended in methanol/water for LC-MS/MS.
The LC-tandem MS/MS system, QTrap 5500 (ABSciex), was equipped with an Agilent
HP1100 binary pump. An Agilent Eclipse Plus C18 column (50 mm x 4.6 mmx 1.8 μm or
100 mm x 4.6 mm x 1.8 μm) was used with a gradient of methanol/water/acetic acid of
60:40:0.01 (volume/volume/volume) to 100:0:0.01 at 0.5-ml/min flow rate. To monitor and
quantify the levels of the various LV and spleen lipid mediators, a multiple reaction
monitoring method was developed with signature ion fragments for each molecule.
Identification was conducted using published criteria with at least 6 diagnostic ions to match
the ions in MS-MS spectra and retentions obtained for both authentic and synthetic
standards. Calibration curves were obtained using synthetic and authentic LM mixtures (they
included d8–5S-HETE, d4-LTB4, d5-LXA4, d4-PGE2, RvD1, RvD2, RvD5, PD1, MaR1,
RvE1, RvE2, LXA4, LXB4, LXA5, PGE2, PGD2, PGF2α, thromboxane B2 (TXB2), PGE3,
PGF3α, TXB3, LTB4, 17-HDHA, 14-HDHA, 7-HDHA, 4-HDHA, 18-HEPE, 15-HEPE, 12HEPE, 5-HEPE, 15-HETE, 12-HETE, and 5-HETE) at 12.5, 25, 50, 100 pg. Linear
calibration curves for each were obtained with r2 values in the range 0.98–0.99. If a
synthetic or biogenic standard for a given product were not available (such as for LXB5 and
PGD3), calibration curves for products with similar chromatographic behaviors (namely, tri-,
di-, or mono-HETEs) to the analyte of interest were used. Quantification was carried out
based on the peak area of the MRM transition and the linear calibration curve for each
compound (32, 33). All SPMs and prostanoids were identified in accordance with published
criteria (32) which included matching retention times, fragmentation patterns, and at least 6
characteristic and diagnostic ions for each as illustrated within the results.
Macrophage depletion

Author Manuscript

To deplete macrophages, a suspension of clodronate liposomes (Clophosome®; FormuMax
Scientific Inc) was prepared for subcutaneous injection (35μg/g body weight) as per the
manufacturer’s instructions. Briefly, clodronate was injected 24 h (hours) prior to coronary
artery ligation and then 3 h post ligation. Post 24 h coronary artery ligation spleen and LV
were collected as described above.
Quantitative Real-Time PCR
For qPCR, reverse transcription was performed for both LV and spleen using equal amount
of total RNA (2.5μg) using SuperScript® VILO cDNA Synthesis Kit (Invitrogen, CA, USA).
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Quantitative PCR for ALOX15 (Mm00507789_m1), ALOX12 (Mm00545833_m1), ALOX5
(Mm01182747_m1), COX-1 (Mm00477214_m1) and COX-2 (Mm00478374_m1) genes
was performed using taqman probes (Applied Biosystems, CA, USA) on master cycler ABI,
7900HT. Gene expression was normalized to the housekeeping control gene Hprt-1
(Mm01545399_m1) (which encodes hypoxanthine phosphoribosyltransferase). The results
were reported as 2−ΔCt (ΔΔCt) values. All the experiments were performed in duplicates
with n=4 mice/group/day.
Flow cytometry
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Single mononuclear cells were isolated from d0 naïve controls and at post-MI d1 and d5.
Infarcted LV and spleen of male C57Bl/6J mice were analyzed by flow cytometry (24). Prior
to isolation, LV was perfused as described above to remove blood traces. The cell count for
LV mononuclear cells or splenocytes were adjusted to ~1–2 million cells/stain. Isolated cell
suspensions were finally suspended in 200μl of 1:500Fc block and incubated for 10 min on
ice. A cocktail of fluorophore-labeled monoclonal antibodies in 2X concentration were
added for 30 min on ice as appropriate for each set. We used CD45-PE (BD Biosciences),
CD11b-APC, F4/80-Percp (molecular probes), Ly6C-FITC (BD Biosciences), Ly6G-pacific
blue (e-bioscience) and CD206-PE (Biolegend) in cocktail. All populations were first gated
using CD45+ as a marker for hematopoietic cells. Further, the neutrophils were defined as
CD11b+/Ly6G+ cells. Activated macrophages were defined as cells with dual expression of
CD11b (Mac-1) and the surface marker F4/80+. The macrophages (F4/80+) were also
classified as M1 (classically activated macrophages) or M2 (alternatively activated
macrophages) based on Ly6Chigh/CD206− and Ly6Clow/CD206+ respectively. Similarly,
neutrophils were defined as N1 (Ly6G+/CD206−) and N2 (Ly6G+/CD206+). Data were
acquired on BDTM LSRII Flow Cytometer and analyzed with FlowJo software, version
7.6.3. The gating strategy is shown in Fig S8.
LV and spleen inflammatory array
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To understand the kinetics of inflammatory response and to reach target specific approach
post-MI, simultaneously in LV and spleen we did 84 gene-expression arrays. Frozen samples
for d0 control and post-MI d1 or d5 from infarcted LV (LVI) and spleen were processed
separately for RNA extraction. LVI and spleen tissue (4–8 mg) was homogenized with a
sonic dismembrator (Fisher Scientific Inc. USA, amplitude between 10–100) and RNA was
isolated using TRIzol (Invitrogen) as per the manufacturer’s instructions. RNA
concentrations were determined using the ND1000 Nano drop. cDNA synthesis was
performed RT2 first strand kit (Qiagen 330401) using 400ng RNA per sample. LV sample
gene expression was prepared using RT2-profiler PCR array [Inflammatory Cytokine and
Receptor by Qiagen (PAMM-011E)] and run on an ABI 7900HT. Gene expression levels
were normalized to the housekeeping control gene Hprt-1. The results were reported as
normalized expression values (23, 31).
Statistical analysis
Data are expressed as mean±SEM. One-way ANOVA post-hoc Kruskal-Wallis was used to
compare measures with ≥2 independent groups. Comparisons between groups (no-MI
control, d1 and d5 post-MI) were performed with Dunn multiple-comparisons test when the
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ANOVA test was statistically significant. The Mann–Whitney test was used to compare 2
groups. A value of p<0.05 was considered significant.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Acknowledgments:
We thank Iliyan Vlasakov of the Center for Experimental Therapeutics and Reperfusion Injury for expert technical
assistance in sample preparation for LC-MS-MS.
Funding: This work was supported by National Institutes of Health [AT006704 and HL132989] and The University
of Alabama at Birmingham (UAB) Pittman scholar award to G.V.H., American Heart Association postdoctoral
fellowship [POST31000008] to V.K. and [P01-GM095467 and GM038765–30] to C.N.S.

Author Manuscript

References and Notes

Author Manuscript
Author Manuscript

1. Kain V, Prabhu SD, Halade GV, Inflammation revisited: inflammation versus resolution of
inflammation following myocardial infarction. Basic Res Cardiol 109, 444 (2014). [PubMed:
25248433]
2. Prabhu SD, Frangogiannis NG, The Biological Basis for Cardiac Repair After Myocardial
Infarction: From Inflammation to Fibrosis. Circ Res 119, 91–112 (2016). [PubMed: 27340270]
3. Tourki B, Halade G, Leukocyte diversity in resolving and nonresolving mechanisms of cardiac
remodeling. FASEB J 31, 4226–4239 (2017). [PubMed: 28642328]
4. Serhan CN, Yacoubian S, Yang R, Anti-inflammatory and proresolving lipid mediators. Annual
review of pathology 3, 279–312 (2008).
5. Tabas I, Glass CK, Anti-inflammatory therapy in chronic disease: challenges and opportunities.
Science 339, 166–172 (2013). [PubMed: 23307734]
6. Frangogiannis NG, Regulation of the inflammatory response in cardiac repair. Circ Res 110, 159–
173 (2012). [PubMed: 22223212]
7. Nahrendorf M, Frantz S, Swirski FK, Mulder WJ, Randolph G, Ertl G, Ntziachristos V, Piek JJ,
Stroes ES, Schwaiger M, Mann DL, Fayad ZA, Imaging Systemic Inflammatory Networks in
Ischemic Heart Disease. J Am Coll Cardiol 65, 1583–1591 (2015). [PubMed: 25881940]
8. Bolli R, Reflections on the Irreproducibility of Scientific Papers. Circ Res 117, 665–666 (2015).
[PubMed: 26405183]
9. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo
JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet
MJ, Identification of splenic reservoir monocytes and their deployment to inflammatory sites.
Science 325, 612–616 (2009). [PubMed: 19644120]
10. Serhan CN, Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101
(2014). [PubMed: 24899309]
11. Funk CD, Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug
Discov 4, 664–672 (2005). [PubMed: 16041318]
12. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, Use of nonsteroidal
antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart
Association. Circulation 115, 1634–1642 (2007). [PubMed: 17325246]
13. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, Iwamoto Y, Thompson B,
Carlson AL, Heidt T, Majmudar MD, Lasitschka F, Etzrodt M, Waterman P, Waring MT, Chicoine
AT, van der Laan AM, Niessen HW, Piek JJ, Rubin BB, Butany J, Stone JR, Katus HA, Murphy
SA, Morrow DA, Sabatine MS, Vinegoni C, Moskowitz MA, Pittet MJ, Libby P, Lin CP, Swirski
FK, Weissleder R, Nahrendorf M, Myocardial infarction accelerates atherosclerosis. Nature 487,
325–329 (2012). [PubMed: 22763456]

Sci Signal. Author manuscript; available in PMC 2018 September 19.

Halade et al.

Page 13

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

14. Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd JH, Fayad ZA, Lehrer-Graiwer J,
Korsgren M, Figueroa AL, Fredrickson J, Rubin B, Hoffmann U, Truong QA, Min JK, Baruch A,
Nasir K, Nahrendorf M, Tawakol A, Splenic metabolic activity predicts risk of future
cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging
8, 121–130 (2015). [PubMed: 25577441]
15. Ma Y, Yabluchanskiy A, Iyer RP, Cannon PL, Flynn ER, Jung M, Henry J, Cates CA, DeleonPennell KY, Lindsey ML, Temporal neutrophil polarization following myocardial infarction.
Cardiovasc Res 110, 51–61 (2016). [PubMed: 26825554]
16. Leuschner F, Rauch PJ, Ueno T, Gorbatov R, Marinelli B, Lee WW, Dutta P, Wei Y, Robbins C,
Iwamoto Y, Sena B, Chudnovskiy A, Panizzi P, Keliher E, Higgins JM, Libby P, Moskowitz MA,
Pittet MJ, Swirski FK, Weissleder R, Nahrendorf M, Rapid monocyte kinetics in acute myocardial
infarction are sustained by extramedullary monocytopoiesis. The Journal of experimental medicine
209, 123–137 (2012). [PubMed: 22213805]
17. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD, Remodeling of the
mononuclear phagocyte network underlies chronic inflammation and disease progression in heart
failure: critical importance of the cardiosplenic axis. Circ Res 114, 266–282 (2014). [PubMed:
24186967]
18. Aurora AB, Porrello ER, Tan W, Mahmoud AI, Hill JA, Bassel-Duby R, Sadek HA, Olson EN,
Macrophages are required for neonatal heart regeneration. J Clin Invest 124, 1382–1392 (2014).
[PubMed: 24569380]
19. Libby P, Nahrendorf M, Swirski FK, Leukocytes Link Local and Systemic Inflammation in
Ischemic Cardiovascular Disease: An Expanded “Cardiovascular Continuum”. J Am Coll Cardiol
67, 1091–1103 (2016). [PubMed: 26940931]
20. Blomer N, Pachel C, Hofmann U, Nordbeck P, Bauer W, Mathes D, Frey A, Bayer B, Vogel B, Ertl
G, Bauersachs J, Frantz S, 5-Lipoxygenase facilitates healing after myocardial infarction. Basic
Res Cardiol 108, 367 (2013). [PubMed: 23812248]
21. Fredman G, Ozcan L, Spolitu S, Hellmann J, Spite M, Backs J, Tabas I, Resolvin D1 limits 5lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated
kinase pathway. Proc Natl Acad Sci U S A, (2014).
22. Kain V, Ingle KA, Colas RA, Dalli J, Prabhu SD, Serhan CN, Joshi M, Halade GV, Resolvin D1
activates the inflammation resolving response at splenic and ventricular site following myocardial
infarction leading to improved ventricular function. J Mol Cell Cardiol 84, 24–35 (2015).
[PubMed: 25870158]
23. Ma Y, Halade GV, Zhang J, Ramirez TA, Levin D, Voorhees A, Jin YF, Han HC, Manicone AM,
Lindsey ML, Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture
after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res 112, 675–
688 (2013). [PubMed: 23261783]
24. Halade GV, Kain V, Black LM, Prabhu SD, Ingle KA, Aging dysregulates D- and E-series
resolvins to modulate cardiosplenic and cardiorenal network following myocardial infarction.
Aging (Albany NY) 8, 2611–2634 (2016). [PubMed: 27777380]
25. Lopez EF, Kabarowski JH, Ingle KA, Kain V, Barnes S, Crossman DK, Lindsey ML, Halade GV,
Obesity superimposed on aging magnifies inflammation and delays the resolving response after
myocardial infarction. Am J Physiol Heart Circ Physiol 308, H269–280 (2015). [PubMed:
25485899]
26. Halade GV, Rahman MM, Bhattacharya A, Barnes JL, Chandrasekar B, Fernandes G,
Docosahexaenoic acid-enriched fish oil attenuates kidney disease and prolongs median and
maximal life span of autoimmune lupus-prone mice. Journal of immunology 184, 5280–5286
(2010).
27. Mozaffarian D, Wu JH, Omega-3 fatty acids and cardiovascular disease: effects on risk factors,
molecular pathways, and clinical events. J Am Coll Cardiol 58, 2047–2067 (2011). [PubMed:
22051327]
28. Endo J, Sano M, Isobe Y, Fukuda K, Kang JX, Arai H, Arita M, 18-HEPE, an n-3 fatty acid
metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac
remodeling. J Exp Med 211, 1673–1687 (2014). [PubMed: 25049337]

Sci Signal. Author manuscript; available in PMC 2018 September 19.

Halade et al.

Page 14

Author Manuscript

29. Halade GV, Kain V, Ingle KA, Heart Functional and Structural Compendium of Cardiosplenic and
Cardiorenal Networks in Acute and Chronic Heart Failure Pathology. Am J Physiol Heart Circ
Physiol, ajpheart 00528 02017 (2017).
30. Bauer M, Cheng S, Jain M, Ngoy S, Theodoropoulos C, Trujillo A, Lin FC, Liao R,
Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in
mice. Circ Res 108, 908–916 (2011). [PubMed: 21372284]
31. Halade GV, Ma Y, Ramirez TA, Zhang J, Dai Q, Hensler JG, Lopez EF, Ghasemi O, Jin YF,
Lindsey ML, Reduced BDNF attenuates inflammation and angiogenesis to improve survival and
cardiac function following myocardial infarction in mice. Am J Physiol Heart Circ Physiol 305,
H1830–1842 (2013). [PubMed: 24142413]
32. Dalli J, Serhan CN, Specific lipid mediator signatures of human phagocytes: microparticles
stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120, e60–72 (2012).
[PubMed: 22904297]
33. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN, Identification and signature profiles for
pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 307,
C39–54 (2014). [PubMed: 24696140]

Author Manuscript
Author Manuscript
Author Manuscript
Sci Signal. Author manuscript; available in PMC 2018 September 19.

Halade et al.

Page 15

Author Manuscript
Author Manuscript
Author Manuscript

Figure 1. Infarcted LV healing is associated with expression of different LOX isoforms in mice
post-MI.

Author Manuscript

A. Study design. B. Fractional shortening (%) measured from the long axis. n=6 mice/group/
day. C. Post-MI percentage of LV infarcted area compared to naïve controls with no infarct.
n=6 mice/group/day. D. Representative echocardiographic long axis B-mode images of
naïve control, and post-MI d1 and d5. E and F. Representative images from horizontal
sections of LV mid-cavity stained with (E) hematoxylin and eosin and (F) picrosirius red.
Scale bar, 50 μm. n=6 mice/group/day. G to I. Expression analysis of (G) ALOX15, (H)
ALOX12, (I) and ALOX5 in infarcted LV or spleen from naïve control mice or at the
indicated time points after MI. Expression was normalized to Hprt-1. n=6 mice/group/day. JK. Expression analysis of (J) COX-2 and (K) COX-1 in infarcted LV from naïve control
mice or at the indicated time points post-MI. LOX and COX gene expression was
normalized to Hprt-1. N=6 mice/group/day. *p<0.05 compared to no-MI naïve control and
$p<0.05 compared to spleen at respective day time point using one way ANOVA.
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Figure 2. SPM biosynthesis peaked in the infarcted LV and was reduced in spleen post-MI within
24 h.
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A. Pie chart representing the distribution of SPMs and docosahexaenoic acid (DHA),
eicosapentaenoic acid (EPA) and arachidonic acid (AA) in infarcted LV from naïve control
mice or at the indicated time points post-MI. n=4 mice/group/day. B. Pie chart representing
the distribution of SPMs and docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and
arachidonic acid (AA) metabolome in spleen from naïve control mice or at the indicated
time points post-MI. Percentage of mean values for each of the lipid mediators identified are
presented in the pie chart. n=4 mice/group/day. Quantification and values are pg/ 50 mg LV
tissue from apex to base and pg/50mg spleen tissue. The detection limit was ~1 pg.
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Figure 3. Infarcted LV macrophage activation is inversely proportional to lipoxin kinetics in the
spleen within 24 h post-MI.
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A. Representative flow cytometry (FACs) dot plots showing the macrophage population
(CD11b+/F4/80+) in spleen (left panel) and LV mononuclear cells (right panel) in no-MI
naïve control and at d1 and d5 post-MI. B. Line graph showing the percentage of the F4/80+
population in spleen and LV mononuclear cells at d0, post-MI d1 and d5. n=4 mice/group/
day. C. Line graph showing the kinetics of LTB4 in LV and spleen in no-MI control and at
d1 and d5 post-MI. n=4 mice/group/day. D. Line graph showing the kinetics of LXB4 in noMI control and at d1 and d5 post-MI in LV and spleen. n=4 mice/group/day. E. Line graph
showing the kinetics of AT-LXA4 in LV and spleen in no-MI control and at d1 and d5 postMI. Results are mean±SEM. Quantification and values in C, D, and E are pg/50 mg of
spleen or infarcted LV tissue from apex to base. The detection limit was ~1 pg. *p<0.05
compared to no-MI naïve control and $p<0.05 compared to spleen at respective day time
point using one way ANOVA.
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Figure 4. Infarcted LV contains activated leukocytes and SPM biosynthesis is increased in spleen
and infarcted myocardium post-MI.

Author Manuscript

A. Representative flow cytometry (FACs) dot plots showing the neutrophil population
(CD11b+/Ly6G+) in spleen (left panel) and LV mononuclear cells (right panel) in no-MI
naïve control and at d1 and d5 post-MI. B. Line graph showing the percentage of the Ly6G+
population in spleen and LV mononuclear cells at d0, and d1 and d5 post-MI. n=4 mice/
group/day. C. Line graph showing the kinetics of RvD1 in LV and spleen in no-MI control
and at d1 and d5 post-MI. n=4 mice/group/day. D. Line graph showing the kinetics of RvD5
in LV and spleen at d1 and d5 post-MI compared to spleen and LV d0 naïve controls. n=4
mice/group/day. Quantification and values in C and D are pg/50 mg of spleen or infarcted
LV tissue from apex to base. *p<0.05 compared to no-MI naïve control and $p<0.05
compared to spleen at respective day time point using one way ANOVA.
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Figure 5. Splenic monocyte/macrophage subsets (F4/80+/Ly6Clow) that increase in the infarcted
LV within 24 h are associated with biosynthesis of maresin 1 (MaR1).
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A. Representative flow cytometry (FACs) dot plots showing macrophage population
(F4/80+/Ly6C+) in spleen (left panel) and LV mononuclear cells (right panel) in no-MI naive
control and at d1 and d5 post-MI. B. Line graph showing the percentage of the Ly6Chigh
population in spleen and LV mononuclear cells at d0, d1 and d5 post-MI. n=4 mice/group/
day. C. Line graph showing the percentage of the Ly6Clow population in spleen and LV
mononuclear cells in d0 naïve controls and at d1 and d5 post-MI. n=4 mice/group/day. D.
Line graph showing the kinetics of MaR1 in LV and spleen in no-MI control and at d1 and
d5 post-MI. n=4 mice/group/day. Results are mean±SEM. Quantification and values of
analytes are pg/50 mg of spleen or LV infarct tissue from apex to base. The detection limit
was ~1 pg. *p<0.05 compared to no-MI naïve control. $p<0.05 compared to spleen at
respective day time point using one way ANOVA.
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Figure 6. Leukocyte activation in infarcted LV and spleen is associated with overlapping
inflammatory and resolving phenotypes.
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A. Representative histogram overlay of inflammatory and resolving leukocytes in LV. n=4
mice/group/day. B. Representative histogram overlay of inflammatory and resolving
leukocytes in spleen. n=4 mice/group/day. C-F. Line graphs showing the kinetics of the C.
Ly6G−/CD206+ D. Ly6G+/CD206+ E. Ly6Chigh/CD206+ F. and Ly6Clow/CD206+
populations in LV and spleen. Results are expressed as mean±SEM, n=4 mice/group/day.
*p<0.05 compared to no-MI naïve control and $p<0.05 compared to spleen at respective day
time point using one way ANOVA (Mo; monocytes, Neu; Neutrophils, M⊘; macrophages;
N2 resolving neutrophils, M2; resolving macrophages)
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Figure 7. Macrophage depletion reduced LOXs expression thereby SPMs post-MI.
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A. Scheme illustrating the experimental design for clodronate (CLD) treatment in MI model.
B. Representative flow cytometry (FACs) dot plots showing the monocyte population
(CD11b+CD45+) mononuclear cells in spleen (upper panel) and infarcted LV (lower panel)
in MI-control and CLD injected mice. C. Bar graph representing CD11b+ cells. D. FACs dot
plots showing the mononuclear macrophage population (CD11b+F4/80+) in spleen (upper
panel) and infarcted LV (lower panel) in MI-control and CLD-injected mice. E. Bar graph
representing F4/80+ cells (open bar MI-control and filled bar MI+CLD). n=4 mice/group. FH. Gene expression analysis of F. ALOX15, G. ALOX12, H ALOX5, in infarcted LV postMI in CLD-injected mice. Gene expression was normalized to Hprt-1. n=4 mice/group. I-J.
Gene expression analysis of I. COX-2, J. COX-1 in infarcted LV post-MI in CLD-injected
mice. Gene expression was normalized to Hprt-1. n=4 mice/group. *p<0.05 compared to MI
control and $p<0.05 compared to spleen using one way ANOVA. K-P. Measurement of K.
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LXA4, L. AT-LXA4, M. RvD4, N. LTB4, O. LXB4, and P. PGE2 in spleen (open bar) and
infarcted LV (filled bar) at day 1 post-MI after CLD-mediated macrophage depletion.
Results are Mean±SEM values; n=3 mice/group. Quantified values of analytes are pg/50 mg
of spleen or LV infarct tissue from apex to base. The detection limit was ~1 pg.
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Figure 8. Activated cytokine and chemokine signal is amplified early in spleen than LV in postMI resolution of inflammation.
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A-F. mRNA expression of A. IL-1b, B. Ccl2, C C3, D. IL-10, E. CxCL10, and F. Ccr6 in
spleen or infarcted LV from naïve control mice or at the indicated time points post-MI.
Results are expressed as mean±SEM, n=4 mice/group. *p<0.05 compared to no-MI naïve
control and $p<0.05 compared to spleen at respective day time point using one way
ANOVA. G. Model showing that leukocytes in the spleen generated SPMs through LOX
isoforms that advance the resolution of inflammation and healing in the LV post-MI.
Clodronate (CLD)-mediated macrophage depletion reduced the expression of LOX isoforms
and generation of SPMs, thereby triggering non-resolving inflammation that can lead to HF.
H. Model showing that post-MI, LOXs are preferentially activated in the infarcted LV to
generate SPMs that promote cardiac repair.
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MI-induced edema in LV is marked with splenic mass depletion.
Parameters

No-MI (naïve controls)

MI day 1

MI day 5

10

10

10

Body weight (g)

22.4 ± 1.0

24.3 ± 1.6

21.9 ± 0.6

LV weight (mg)

72.1 ± 2.0

85.4 ± 5.3*

100.6 ± 2.4*

Spleen weight (mg)

62.5 ± 3.2

53.4 ± 4.9*

80.8 ± 5.3*

LV/tibia

4.3 ± 0.1

5.1 ± 0.3*

6.1 ± 0.1*

Lung weight (mg)

154 ± 19

142 ± 13

184 ± 22*

Mice (n)

LV; left ventricle, MI; myocardial infarction,

*

P<0.05 compared to no-MI naïve controls by ANOVA
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